Theme: Discoveries and Developments for Safer Medication

Drug Monitoring 2016

Drug Monitoring 2016

We welcome you to the 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics which is scheduled to be held during August 25-26, 2016 at Philadelphia, USA.

Drug monitoring conferences has theme as “Discoveries and Developments for Safer Medications”. The focus will be mainly on the Therapeutic Drug Monitoring and Toxicogenomics, factors influencing them, challenges, methods followed, rapidly-emerging techniques and their applications.Therapeutic drug monitoring means concentrations of drugs in body fluids, usually plasma, this can be used for diagnostic purposes and during treatment. The selection of drugs for therapeutic drug monitoring is important as the effects of many drugs is not clearly related to their concentrations. Therapeutic drug monitoring is the  clinical practice of measuring concentration of specific drugs in a patient's bloodstream at designated intervals to maintain a constant concentration, thereby optimizing individual dosage regimens. Quantification of Drugs using the analytical methods helps in predicting the toxicological effects.

Track 1: Drug Monitoring

Therapeutic drug monitoring is defined as the clinical laboratory measurement of a chemical parameter that will directly influence drug prescribing procedures after appropriate medical interpretation. TDM refers to maintaining blood drug or plasma concentrations within a targeted therapeutic range or window for the individualization of drug dosage. Drug Monitoring begins after the drug is first prescribed, and involves determining an initial dosage regimen appropriate for the clinical condition and patient characteristics like age, organ function, weight and concomitant drug therapy.

Related Pharmaceutical Conferences | Drug Monitoring Conferences | Drug Delivery Conferences

8th International Conference on Novel Drug Delivery Systems,  March 07-09, 2016, Spain; 2nd Drug Discovery Conference & Designing,  October 24-26, 2016, Turkey ; 4th International Computer Aided Drug Designing Conference, November 02-04, 2015, USA; 7th Annual Global  Pharma Summit, June 20-22, 2016, USA ; 9th World Drug Delivery Summit, June 30-July 02, 2016, USA ; 14th Therapeutic Drug monitoring and Clinical Toxicology Conference, October 11-15, Netherlands, Midwest Association for Toxicology and Therapeutic Drug Monitoring Conferences, April 14-15, 2016, USA; 9th Annual Pain & Migraine Therapeutics Summit, September 23-24, 2015 USA, Americas Drug Safety Congress, April 20-21, 2016, USA, 2nd Annual Formulation & Drug Monitoring USA Congress, May 18-19, 2016, USA; ANZ Therapeutic Drug Monitoring Workshop; MATT : Midwest Association for Toxicology and Therapeutic Drug Monitoring;  IATDMCT: International Association of Therapeutic Drug Monitoring and Clinical Toxicology; SOTSociety of ToxicologyBTSBritish Toxicology Society

Track 2: Pharmacokinetics & Pharmacodynamics

Pharmacokinetics involves the measurement of the time course of drug absorption, distribution, metabolism and excretion. Clinical pharmacokinetics means the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Pharmacodynamics means the relationship between drug concentration at the site of action and the resulting effect, intensity of therapeutic and adverse effects and including the time course. Therapeutic treatment requires information on both pharmacokinetics and pharmacodynamics to understand interpatient variability and how to prescribe dosage for body size, age, or genetic traits. Clinical pharmacokinetic drug trials when compiled for numerous drugs can reveal metabolism and excretion differences across age groups. If sufficient clinical pharmacokinetic data is available, it may be possible to make inferences about the handling of environmental toxicants in a particular age group.

Related Pharmaceutical Conferences Pharmacokinetic Conferences | Clinical Pharmacy Conferences | 

7th Annual Global Pharma Summit, June 20-22, 2016, USA; World Pharma Congress,  November 07-November 09, 2016, USA; Pharmaceutical Summit and Expo October 08-10, 2015, India;  6th Asia-Pacific Pharma Congress  July 11-13, 2016, Malaysia; 8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Conference, March 07-09, 2016, Spain; 2nd Annual Drug Discovery Congress, October 29-30,2015, USA, Drug Discovery Congress 2016, Boston, USA; 10th Drug Design and Medicinal Chemistry, May 09-10, 2016, Germany; Drug Discovery week Europe, October 05-08, 2015, Germany; 3rd Antibody & Protein Therapeutics, October 22-23, 2015, USA; 4th Immunogenicity & Immunotoxicity, January 25-26,2016, USA; IATDMCT: International Association of Therapeutic Drug Monitoring and Clinical ToxicologyACCPAmerican College of Clinical PharmacyUKCPAUnited Kingdom Clinical Pharmacy AssociationESCPThe European Society of Clinical Pharmacy; Royal Pharmaceutical Society

Track 3: Gender & Pathophysiology

The ADME of a drug determines the Serum Concentration of a particular drug. Serum drug concentration  is mainly affected by characteristics like genetic makeup, pathophysiology condition and various other factors. The metabolism of drugs in patient with renal failure may slowly clears a drug in urine than a patient with normal renal function. Pregnancy state in women alters the drug metabolism and drug-drug interactions may also alter serum drug concentration. Anatomical variations and different metabolism rates of specific drugs in men and women may show both pharmacokinetic and pharmacodynamics differences.

Related Toxicology Conferences | Pathology Conferences | Drug Monitoring Conferences

5th International Pathology Conference May 09-11, 2016, USA; World Digital Pathology Congress October 31-November 02, 2016, Spain; International Internal Medicine Conference November 03-05, 2016, USA; International Conference on Speech-Language Pathology November 14-15, 2016 Atlanta, USA; International Conference on Cytology & Histology August 01-03, 2016, UK; Pathology Summit Update 2016, February 26-28, 2016, Australia; American society for Clinical Pathology Annual Meeting, October 28-30, 2015, USA; 29th Annual Park city Anatomic Pathology Update, February 7-11, 2016, USA, 10th  Drug Design and Medicinal Chemistry, May 09-10,2016, Germany; European Pharma Summit, May 09-11, 2016, Germany; ESCP: The European Society of Clinical Pharmacy; Pharmaceutical Society of Australia; National Pharmacy Association; ACCP: American College of Clinical Pharmacy; American Society for Clinical Pharmacology and Therapeutics

Track 4: Individual Drugs TDM

Anti-epileptic drugs have a narrow therapeutic range as they are strongly bound to serum proteins. Cardio active drugs Digoxin which is frequently used has a narrow therapeutic window. The immunoassays employed in monitoring concentration of serum digoxin are subjected to interference from both exogenous and endogenous compounds. Anti-asthmatic drugs like theophylline and caffeine also require Therapeutic Drug Monitoring. Antidepressants monitoring is essential to avoid drug toxicity. Immunosuppressant’s Whole blood concentration is determined to avoid drug toxicity as well as subtherapeutic levels which may lead to organ rejection. Antibiotics like aminoglycoside produce Nephrotoxicity and Ototoxicity for which they are monitored.

Related Toxicology Conferences | Pharmaceutical Conferences | Drug Discovery Conferences

4th  Annual conferences on European Pharma Congress, June 13-15, 2016, Germany; 2nd  International Conference on Drug Discovery & Designing, October 24-26, 2016, Turkey; 9th  World Drug Delivery Summit, June 30-July 02, 2016, USA;  8th  International Conference on Novel Drug Delivery Systems, March 07-09, 2016, Spain; 7th  Annual Global Pharma Summit   June 20-22, 2016, USA; 18th  International Conference on Toxicogenomics Conferences, Drug Monitoring and Toxicology, February 1-2, 2016, Brazil; 9th Annual Pain & Migraine Toxicogenomics 2016 Summit, September 23-24, 2015 USA, World Drug Monitoring USA, April 20-21, 2016, USA, 2nd Annual Formulation & Drug Delivery Congress, May 18-19, 2016, UK; European Pharma Summit, May 09-11, 2016, Germany; SASOCP: South African Society of Clinical Pharmacy; American Society of Clinical Pharmacists; EAHP: European Association of Hosiptal Pharmacists; American College of Toxicology; ANZ Therapeutic Drug Monitoring Workshop

Track 5: Drug Quantification

Drug assay methods should have adequately sensitivity. They should be specific to the drug metabolites which has to be measured and should be accurate and precise. Most of the high-volume drug assays are now performed with the automated immunoassay methods which possess these characteristics. However, many a number continue to require manual assay procedures like HPLC and GLC (e.g. amiodarone, perhexiline). Depending on the equipment used, plasma or serum are usually used for drug assays.

Related Analysis Conferences | Toxicology Conferences | Pharmacological Conferences

7th International Conference on Analytical & Bioanalytical Techniques, September 29-October 01, 2016, USA; 2nd International Conference on Separation Techniques, November 03-05, 2016, Spain; International Conference on Biopharmaceutics, September 21-22, 2015, USA; 2nd  International Mass Spectrometry Conference, May 09-11, 2016, USA; 4th  Annual conferences on European Pharma Congress, June 13-15, 2016, Germany; 2016 Winter Conference on Plasma Spectrochemistry, January 10-16, 2016, USA; International Forum Process Analysis & Control, January 24-27, 2016, USA; Structure  Based Drug Monitoring USA Conference 2016, February 21-24, 2016, USA, 1st International Conference on Applied Chemistry, March 14-17, 2016, Egypt; Experimental Nuclear Magnetic Resonance Conference 2016, April 10-15, USA; DATIA: Drug and Alcohol Testing Industry Association; National Pharmacy Association; Royal Pharmaceutical SociteyANZ Therapeutic Drug Monitoring WorkshopMATT : Midwest Association for Toxicology and Therapeutic Drug Monitoring;

Track 6: TDM Challenges 

Therapeutic Drug Monitoring depends on Chemical Analysis, Pharmacokinetics and Pharmacodynamics. By determining the nature of the problem to be solved, appropriate methodology to solve the problem, developing applicable analytical schemes that have to be performed competently with good quality and interpreted within the framework, analytical goals in therapeutic drug monitoring should be established. If plasma drug concentration measurements are to be of any particular value, blood sampling timing, the type of blood sample, the measurement technique, and the interpretation of results are to be done with attention. After dosing, it is crucial to obtain the blood sample for measuring the drug concentration at the correct time. Errors in the sampling times are likely responsible for the errors in interpreting the results.

Related Toxicology Conferences | Pharmaceutical Conferences | Genomic Conferences

4th Annual conferences on European Pharma Congress, June 13-15, 2016, Germany; World Pharma Congress, October 31-November 02, 2016, USA; Pharmaceutical Summit and Expo, October 08-10, 2015, India; 7th International Conference on Analytical & Bioanalytical Techniques, September 29-October 01, 2016 Miami, USA; 8th  International Conference on Pharmaceutics & Novel Drug Delivery Systems, March 07-09, 2016, Spain; 14th  Therapeutic Drug Monitoring Confernces and Clinical Toxicology Conference, October 11-15, Netherlands, Midwest Association for Toxicology and Therapeutic Drug Monitoring, April 14-15, 2016, USA; 17th  Annual Toxicogenomics 2016 Summit, June 2016, Germany; 2nd  Annual Formulation & Drug Delivery Congress, May 18-19, UK; European Pharma Summit, May 09-11, 2016, Germany; EAHP: European Association of Hosiptal PharmacistsAmerican College of ToxicologyANZ Therapeutic Drug Monitoring WorkshopESCPThe European Society of Clinical PharmacyPharmaceutical Society of Australia; National Pharmacy Association

Track 7 : TDM Advances

Clinician with good insight into the factors determining the patient’s response to drug therapy can use drug monitoring data. In certain conditions were a patient fails to respond to a usual therapeutic dose, measurement of plasma level can help to determine who is a true non-responder and who is a noncompliant patient. Therapeutic Drug Monitoring also provides useful information regarding individual changes in drug utilization patterns. Drug Monitoring also provides data in changes in utilization of drug as a consequence of disease process or altered physiological state. TDM is a useful adjunct in treating many patients provided the potential pit falls.

Related Human Genetics Conferences | Toxicology Conferences | Environmental Toxicology Conferences

7th International Analytical Conference, September 29-October 01, 2016, USA; International Conference on Drug Discovery & Designing August 11-13, 2015 Frankfurt, Germany; 6th Asia Pacific Pharma Congress July 11-13, 2016, Malaysia; 8th  International Conference on Novel Drug Delivery Systems, March 07-09, 2016, Spain; 14th  Therapeutic Drug monitoring Conferences and Clinical Toxicology Conference, October 11-15, Netherlands, Midwest Association for Toxicogenomics USA and Therapeutic Drug Monitoring, April 14-15, 2016, USA; 17th  Annual Drug Discovery Summit, June 2016, Germany; 2nd  Annual Formulation & Drug Monitoring USA Congress, May 18-19, USA; European Pharma Summit, May 09-11, 2016, Germany; SASOCPSouth African Society of Clinical PharmacyAmerican Society of Clinical Pharmacists; EAHP: European Association of Hosiptal PharmacistsAmerican College of ToxicologyANZ Therapeutic Drug Monitoring Workshop

Track 8: Toxicogenomics Roles

Toxicity detection requires a means to observe (or measure) specific effects of exposures. Toxicology is focused on changes in an organism as a result of exposure to physical, chemical, or biologic agents. Such changes range from reversible effects like transient skin reactions and chronic diseases like as cancer, or to the extreme end point of death. Studies of whole-animal toxicology may range from single-dose acute to chronic lifetime exposures and they include determination of end points like clinical signs of toxicity, organ and body weight changes, clinical chemistry, and histopathologic responses. Predictive toxicology means the study of how toxic effects noted in humans or model systems can be used to assess risk, predict pathogenesis and prevent human disease. Predictive toxicology not only includes risk assessment but also the practical facilitation of decision making with scientific information.

Related Toxicology Conferences | Pharmacology Conferences | Genomics Conferences

5th  Global Toxicology Summit & Applied Pharmacology, September 19-21, 2016, USA; 6th  Global Toxicology & Applied Pharmacology Conference , October 27-29, 2016, Italy; 2nd International Conference on Pharmacology and Ethnopharmacology, May 02-04, 2016, USA; International Environmental Toxicology Conference and Ecological Risk Assessment, August 25-26, 2016, Brazil; 5th Global Toxicology Summit & Applied Pharmacology, September 19-21, 2016, USA; 7th Society of Environmental Toxicology and Chemistry, October 4-8, 2015, South Africa, Society of Forensic Toxicology, October 18-23, 2015, USA; Environmental Mutagenesis and Genomics Society, September 26-30, USA; European Congress of the European Societies of Toxicogenomics 2016, September 04-07, 2016, Turkey; Epigenomics & Novel Therapeutic Targets, May 26-27, 2016, USA; 18th  International Conference on Toxicogenomics Conferences, Drug Monitoring and Toxicology, February 1-2, 2016; SOT: Society of Toxicology; BTS: British Toxicology Society; Eurotox: Federation of European Toxicologists & European Societies of Toxicology; IUTOX: International Union of Toxicology; ESTIV: European Society of Toxicology In Vitro

Track 9: OMICS Technologies

Toxicogenomic technologies comprises of several different technology platforms which are used for analysis of genomes, proteins, metabolites and transcripts. Genomic technologies includes genome sequencing technologies to derive DNA sequences from genes and other parts of DNA and genotype analysis, to detect sequence variations between individual genes. Transcriptomic technologies measures mRNA expression in a highly parallel assay system, mostly using microarrays. Proteomics studies is the collections of proteins in living systems as the same proteins may be present in multiple modified and variant forms. Metabolomics means the study of small-molecule components of biologic systems.As metabolites reflect the activities of proteins, RNAs and the genes that encode them. Metabolomics provides the functional assessment of diseases and chemical and drug toxicity. Bioinformatics focuses on applying advanced computational techniques to the biologic data and to perform all the genomic technologies.

Related Toxicology Conferences | Genomics Conferences | Metabolomics Conferences

5th  Global Toxicology Summit & Applied Pharmacology, September 19-21, 2016, USA; 6th  Global Summit on Toxicology & Applied Pharmacology Conferences, October 27-29, 2016, Italy; 2nd International Conference  on Pharmacology and Ethnopharmacology, May 02-04, 2016, USA; International Conference on Environmental Toxicology and Ecological Risk Assessment, August 25-26, 2016, Brazil; International Conference on Neuro Genetics, June 06-07, 2016, UK; Environmental Mutagenesis and Toxicogenomics USA Conferences Society, September 26-30, USA;  European Congress of the European Societies of Toxicology 2016, September 04-07, 2016, Turkey, Society of Toxicology of Canada, December 08-10, 2015,  Canada, 8th International Toxicology Conference on , 2018, Thailand,17th International Toxicology Conference, September 25-26, 2015 UK; 18th  International Conference on Toxicogenomics Conferences, Drug Monitoring and Toxicology, February 1-2, 2016; American College of Toxicology; American Society for Clinical Pharmacology and Therapeutics; ASIATOX: The Asian Society of Toxicology; IATDMCT: International Association of Therapeutic Drug Monitoring and Clinical Toxicology; MATT: Midwest Association for Toxicology and Therapeutic Drug Monitoring

Track 10: Adverse Outcome Pathways

An adverse outcome pathway (AOP) is a conceptual framework that organizes existing knowledge concerning biologically plausible, and empirically supported, links between molecular-level perturbation of a biological system and an adverse outcomes at a level of biological organization of regulatory relevance. Systematic organization of information into AOP frameworks has potential to improve regulatory decision-making through greater integration and more meaningful use of mechanistic data. However, for the scientific community to collectively develop a useful AOP knowledgebase that encompasses toxicological contexts of concern to human health and ecological risk assessment, it is critical that AOPs be developed in accordance with a consistent set of core principles. Based on the experiences and scientific discourse among a group of AOP practitioners, we propose a set of five fundamental principles that guide AOP development: (1) AOPs are not chemical specific; (2) AOPs are modular and composed of reusable components-notably key events (KEs) and key event relationships (KERs); (3) an individual AOP, composed of a single sequence of KEs and KERs, is a pragmatic unit of AOP development and evaluation; (4) networks composed of multiple AOPs that share common KEs and KERs are likely to be the functional unit of prediction for most real-world scenarios; and (5) AOPs are living documents that will evolve over time as new knowledge is generated. The goal of the present article was to introduce some strategies for AOP development and detail the rationale behind these 5 key principles. Consideration of these principles addresses many of the current uncertainties regarding the AOP framework and its application and is intended to foster greater consistency in adverse reactions development.

Related Toxicology Conferences | Pharmacology Conferences | Adverse Drug Reaction Conferences

5th  Global Toxicology Summit & Applied Pharmacology, September 19-21, 2016, USA; 6th  Global  Toxicology Summit & Applied Pharmacology, October 27-29, 2016, Italy; 2nd International Conference on Pharmacology and Ethnopharmacology, May 02-04, 2016, USA; International Conference on Environmental Toxicology and Ecological Risk Assessment, August 25-26, 2016, Brazil; International Conference on Neuro Genetics, June 06-07, 2016, UK; Asia Pacific Association of Medical Toxicology, December 1-4, 2015, Western Australia; 7th Society of Environmental Toxicology and Chemistry, October 4-8, 2015, South Africa, Society of Toxicogenomics USA, October 18-23, 2015, USA; Environmental Mutagenesis and Genomics Society, September 26-30, USA; European Congress of the European Societies of Toxicogenomics 2016, September 04-07, 2016, Turkey; ASIATOX: The Asian Society of ToxicologyIATDMCTInternational Association of Therapeutic Drug Monitoring and Clinical ToxicologyMATTMidwest Association for Toxicology and Therapeutic Drug MonitoringSOTSociety of ToxicologyBTSBritish Toxicology Society;

Track 11: Environmental Toxicogenomics

Environmental genomics has revolutionized the study of adverse effects of environmental toxicants. It gives an efficient and high-throughput means to understand the mechanisms of action, risk assessment and to identify and understand basic pathogenic mechanisms that are crucial in disease progression, predicting toxicity and to more precisely phenotype disease subtypes. Environmental genomics in a toxicant exposure model is a crucial tool in biological response marker or biomarker discovery.

Related Environmental Toxicology Conferences | Toxicology Conferences | Toxicogenomics Conferences

International Conference on Environmental Toxicology and Ecological Risk Assessment, August 25-26, 2016, Brazil; 5th Global Toxicology Conference & Applied Pharmacology, September 19-21, 2016, USA; 6th Global Summit on Toxicology & Applied Pharmacology, October 27-29, 2016, Italy; International Conference on Ethnopharmacology, May 02-04, 2016, USA; 6th Asia Pacific Pharma Congress July 11-13, 2016, Malaysia; Biomarker Summit Europe 2015, October 05-08, 2015, Germany; 9th Biomarkers in Drug Discovery & Development, October 05-06, 2015, Germany; 4th Biomarkers in Diagnostics, October 07-08, 2015, Germany; European Pharma Summit, May 09-11, 2015, Germany; Epigenomics & Novel Therapeutic Targets, May 26-27, 2016, USA; 18th  International Conference on Toxicogenomics Conferences, Drug Monitoring and Toxicology, February 1-2, 2016; American College of ToxicologyAmerican Society for Clinical Pharmacology and Therapeutics; ASIATOX: The Asian Society of ToxicologyIATDMCTInternational Association of Therapeutic Drug Monitoring and Clinical ToxicologyMATTMidwest Association for Toxicology and Therapeutic Drug Monitoring

Track 12: Comparative Toxicogenomics

Comparative Toxicogenomics is a research tool that curates scientific data describing relationships between chemicals, drugs and genes, proteins, GO annotations, pathways, diseases, taxa, phenotypes, and interaction modules. Comparative Toxicogenomics gives information on Gene-disease associations, Chemical-disease associations, Chemical-gene interactions and Chemical-phenotype associations.

Related Toxicology Conferences | Toxicogenomics Conferences | Genetic Conferences

International Conference on Environmental Toxicology and Ecological Risk Assessment, August 25-26, 2016, Brazil; 5th Global Summit on Toxicology & Applied Pharmacology, September 19-21, 2016, USA; 6th Global Summit on Toxicology & Applied Pharmacology, October 27-29, 2016, Italy; International Conference on Pharmacology and Ethnopharmacology, May 02-04, 2016, USA; 6th Asia Pacific Pharma Congress July 11-13, 2016, Malaysia; Sequencing & Bioinformatics, October 05-07, 2015, Germany; Protein Discovery Summit, October 23-24, 2015, USA; Single Cell Genomics Conferences & Transcriptomics USA Congress, October 27-28, 2015,USA; American College of Toxicogenomics USA, November 08-11, 2015, USA; The American Academy of Clinical Toxicology, October 08-09, 2015, USA; IATDMCTInternational Association of Therapeutic Drug Monitoring and Clinical ToxicologyMATTMidwest Association for Toxicology and Therapeutic Drug MonitoringSOTSociety of ToxicologyIUTOXInternational Union of ToxicologyESTIVEuropean Society of Toxicology In Vitro

Track 13: Toxicogenomics Challenges

Toxicogenomics challenges include Gene annotation, Cross-species extrapolation, Technical standards for evolving platforms, Standards for data sharing, Biomarker qualification and Translation of assays for regulatory purposes.

Related Toxicology Conferences | Toxicogenomics Conferences | Pharmaceutical Conferences

3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015, USA; World Congress on Human Genetics, October 31- November 02, 2016, Spain; International Conference on Genomic Medicine, August 11-12, 2016, UK; 5th Global Summit on Toxicology & Applied Pharmacology, September 19-21, 2016, USA; 6th Global Summit on Toxicology & Applied Pharmacology, October 27-29, 2016, Italy; European Pharma Summit, May 09-11, 2016, Germany; Epigenomics & Novel Therapeutic Targets, Boston, USA, Genome Editing Congress, August 27-28, 2016, UK; Sequencing & Bioinformatics, October 05-07, 2015, Germany; Protein Discovery Summit, October 22-23, 2015, USA; 18th  International Conference on Toxicogenomics Conferences, Drug Monitoring and Toxicology, February 1-2, 2016; MATTMidwest Association for Toxicology and Therapeutic Drug MonitoringSOTSociety of ToxicologyBTSBritish Toxicology Society; National Pharmacy Association; American Society for Clinical Pharmacology and Therapeutics 

Track 14: Toxicogenomics Applications

As toxicogenomics continues to move forward, it will likely seem at times as if progression is standing still and at other times advancing quickly. In order to advance, key milestones will require coordination across fields and disciplines, so progress is likely to be incremental. Within the next 5 years, it is likely that toxicogenomics will move slowly forward. Biologists will continue to impact the field of informatics, and what constitutes a pathway will be better defined and begun to be standardized universally. In addition, the work of discovery and validation of prodromal biomarkers for a variety of toxicities and diseases will continue to evolve. The advance in technology will no doubt come with reduced cost per sample for analysis and will enable simultaneous probing of genetic, genomic, proteomic and metabolomic events. In the regulatory environment, toxicogenomics biomarker data will routinely be used to better inform the risk assessment from in vitro and in vivo test systems. The acceptance of modified test systems will eventually lead to an impact that minimizes animal testing and allows efficient modelling from human in vitro–based assays and ultra lowdose testing of human subjects to extrapolate and inform toxicity predictions. These models will eventually lead way to predictive in silico models that can help reduce use of animals and cost of experiments conducted to assess hazard and risk.

Related Toxicology Conferences | Proteomics Conferences | Genomics Conferences

World Congress on Human Genetics, October 31- November 02, 2016, Spain; International Conference on Genomic Medicine August 11-12, 2016 Birmingham, UK; 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015, USA; Conference on Genetic Counseling and Genomic Medicine, August 11-12, 2016, UK; 5th Global Summit on Toxicology & Applied Pharmacology, September 19-21, 2016, USA; 17th International Conference on Toxicology, September 25-26, 2015, UK, Genetic Toxicology Association Meeting, May 05-06, USA; Canadian Ecotoxicity Workshop, October 04-07, 2015, Canada; Epigenomics & Novel Therapeutic Targets, Boston, USA, Genome Editing Congress, August 27-28, 2016, UK; European Congress of the European Societies of Toxicogenomics USA 2016, September 04-07, 2016, USA; SOTSociety of ToxicologyBTSBritish Toxicology Society; Eurotox: Federation of European Toxicologists & European Societies of ToxicologyIUTOXInternational Union of ToxicologyESTIVEuropean Society of Toxicology In Vitro

We are pleased to organize 2nd International Conferfence on Therapeutic Drug Moitoring and Toxicogenomics during August 25-26, 2016 at Philadelphia, USA.The Conference mainly focuses on the theme "Discoveries and Developments for Safer Medication".It is an extraordinary event designed for the professionals to facilitate the dissemination and application of research finding on Drug Monitoring and Toxicogenomics.

Drug Monitoring 2016 is a multidisciplinary approach. Drug concentration measurements are requested to assist the management of a patient's current medication regimen or to screen for a medicine. The  Drug Monitoring studies are performed for monitoring drugs with narrow therapeutic ranges, drugs with marked pharmacokinetic variability, medications for which target concentrations are difficult to monitor, and drugs known to cause therapeutic and adverse effects. The process of TDM is predicated on the assumption that there is a definable relationship between dose and plasma or blood drug concentration, and between concentration and therapeutic effects. Accurate and clinically meaningful drug concentrations are attainable only by complete collaboration by a TDM team, typically comprised of scientists, clinicians, nurses, and pharmacists. OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to Attend??

Drug Monitoring 2016 gives you access to leading-edge pharmaceutical information and valuable new professional contact from all over the world. Its large international participation provides excellent opportunities for global sharing of technology, expertise, products, and best practices. There are exhibitions which run in parallel with the conference and offer you the chance to get up-to-date information from companies active in your area of interests. We are grateful to our sponsors and exhibitors for their interest and support for the conference.

Target Audience:

  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Graduates and Post Graduates
  • Directors, CEO’s of Organizations
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Pharmacists
  • Toxicology Professionals
  • Genetic Professionals
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Software development companies
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • Training Institutes
  • Business Entrepreneur

 

Summary:

OMICS International Conferences invites all the participants across the globe to attend 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics during August 25-26, 2016 in Philadelphia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. Drug Monitoring 2016 is a specially designed cluster conference. The main theme of the conference is “Discoveries and Developments for Safer Medication” which covers a wide range of critically important sessions.

For More details please visit: http://toxicogenomics.conferenceseries.com/

Importance and Scope:

Therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse.

Why Philadelphia, USA?

Philadelphia is the largest city in the Commonwealth of Pennsylvania. Widely known as Philly, but formerly known as the City of Philadelphia. It is also called the City of Brotherly Love. The fifth most populous city in the United States, and the core of the sixth-largest metropolitan area in the country. There are nearly 1.5 million people in the city alone. The city is located in the Northeastern United States at the confluence of the Delaware and Schuylkill rivers; Philadelphia is the economic and cultural center of the Delaware Valley.

The city has more outdoor sculptures and murals than any other American city, and Philadelphia’s Fairmount Park is the largest landscaped urban park in the world. The birthplace of America is Philadelphia, the city where the founding fathers lived and the Declaration of Independence was signed. Today that history echoes in the original buildings and museums of the area often called “Historic Philadelphia”. Lacking defined boundaries, Historic Philadelphia covers parts of the Old City and Center City neighborhoods and includes the Independence National Historic Park. Some of the top Historic Philadelphia attractions are not exhaustive, but it does include some of the most popular, interesting and informative places to visit in the area like City Center, Independence National Historical Park, Pennsylvania Academy of Fine Arts Museum, Rittenhouse, Reading Terminal Market, Please Touch Museum, Philadelphia Museum of Art, Franklin Square, Mutter Museum.

Therapeutic drug monitoring (TDM) will spike to $2.69 billion by 2019. Therapeutic drug monitoring can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic drug monitoring market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.

Conference Highlights:

•    Drug monitoring
•    Pharmacokinetics & Pharmacodynamics
•    Gender & Pathophysiology
•    Individual Drugs TDM
•    Drug Quantification
•    TDM Challenges
•    Advances in TDM
•    Toxicogenomics Roles
•    OMICS Technologies
•    Adverse Outcome Pathways
•    Environmental Toxicogenomics
•    Comparative Toxicogenomics
•    Toxicogenomics Challenges
•    Toxicogenomics Applications

Major Associations around the Globe:

•    International Association of Therapeutic Drug Monitoring and Clinical Toxicology
•    Midwest Association for Toxicology and Therapeutic Drug Monitoring
•    Academy of Managed Care Pharmacy (AMCP), Alexandria, VA
•    Society of Toxicology (SOT)
•    Drug Information Association
•    British Columbia Pharmacy Association
•    California Pharmacists Association
•    Kansas Pharmacists Association
•    Society of Toxicology of Canada
•    Toxicology Education Foundation (TEF)
•    International Society of Regulatory Toxicology and Pharmacology

Major Associations in USA:

•    American Academy of Clinical Toxicology
•    American Association for Laboratory Animal Science
•    American Board of Toxicology
•    American Board of Forensic Toxicology
•    American Board of Veterinary Toxicology
•    American Association of Pakistani Pharmaceutical Scientists
•    American College of Toxicology
•    Behavioral Toxicology Society
•    Drug Information Association
•    Ohio Pharmacists Association


Top Universities in USA :

  • Auburn University
  • Samford University
  • Midwestern University
  • The University of Arizona
  • Harding University
  • University of Arkansas for Medical Sciences                        
  • California Health Sciences University
  • Keck Graduate Institute
  • University of California, San Francisco
  • Idaho State University
  • University of Illinois at Chicago
  • The University of Kansas
  • Wayne State University
  • University of Kentucky
  • University of the Pacific

Target Audience:

  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Graduates and Post Graduates
  • Directors, CEO’s of Organizations
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Pharmacists
  • Toxicology Professionals
  • Genetic Professionals
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Software development companies
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • Training Institutes
  • Business Entrepreneur

Target Audience:

  • Industry     50%
  • Academia  40%
  • Others       10%

Glance at the Market:

The global in-vitro toxicology testing market is estimated to reach $17,227 million by 2018 at a CAGR of 13.5% during the forecast period (2013–2018). The market will witness a double-digit growth attributed to the increasing acceptance of in vitro methods over in vivo ones. Government support to stop animal testing, new and promising technologies, and advancement in new approaches are significant factors forcing the market in the forecast period.

Initiation of Tox 21, government programs by the U.S. government and growing number of drug discoveries and innovations globally represent an opportunity for the growth of the market. Detection of the toxic effects much earlier in the development stage, the pharmaceutical industry adapted to in vitro methods apart from the rising pressure to reduce the drug attrition rates to control the drug development costs and time line. The pharmaceutical industry has been witnessing a enormous growth as a result of government initiatives such as AXLR8 program that was initiated by the European Union. The cosmetic industry will grow the fastest owing to the amendment of European Union’s Cosmetics Directive that has set forth ban on the use of animals in testing for any toxic effects of beauty products. Geographic analysis reveals that Europe was the largest contributor to the global in vitro toxicology testing market in 2013. It will also be the fastest growing region till 2018. The European market is witnessing growth as a result of strong government directives to altogether stop animal testing and replace in vivo testing by in vitro methods.

Global in vitro Toxicology market

Toxicogenomics 2015


International Conference on Toxicogenomics and Drug Monitoring was held in Valencia, Spain during August 25-27, 2015. Toxicogenomics 2015 has provided a platform to frame the conference on “Discoveries in Prediction of Toxicity and Drug Monitoring” which served as an excellent opportunity to gain new knowledge, share technical and pharmaceutical experiences, networking with colleagues and communicate with industry partners.

Toxicogenomics-2015 would like to thank the Moderator, Dr. Farhad Kamali, Newcastle University, UK for extending warm support for smooth functioning of the conference.

It was our pleasure to have Dr. Susana Garcia de Arriba, Schaper & Brummer GmbH & Co. KG, Germany to organize a workshop on “Human safety of free hydroquinone derived from herbal medicinal products containing Uvae ursi folium”.

The event witnessed vivacious speeches from Keynote Speakers, Scientists, Researchers, and many other participants targeting diverse areas of Toxicogenomics and Drug Monitoring emphasizing the below scientific tracks:

  • Toxicology Approaches
  • Concept of Toxicogenomics
  • Omics Technologies in Toxicogenomics
  • Biomarkers in Toxicogenomics
  • Drug Monitoring
  • Predictive Human Toxicity and ADME/Tox Studies
  • Genomics Approaches to Predictive Toxicology
  • PK and PD Tools for DNA-Damage Pathways
  • Adverse Outcome Pathways
  • Bioinformatics in Toxicogenomics
  • Environmental Toxicogenomics
  • Animal Modeling in Toxicogenomics and Toxicoproteomics
  • Comparative Toxicogenomics

The conference commenced successfully with the vehement presentations by Eminent Speakers like

Jenny Bosson, Umea University, Sweden

Wilhelm Gaus, University of Ulm, Germany

D Weissmann, Alcediag, France

Raúl Bonne Hernández, Federal University of São Paulo, Brazil

Dinora Vázquez-Luna, Universidad Veracruzana, Mexico

Wafa Soudani, Annaba Medical College, Algeria

Eman Alaaeldin Adbelfattah, Cairo University, Egypt

Gazo I, University of South Bohemia in Ceske Budejovice, Czech Republic

OMICS International, on behalf of the Conference, congratulates all the speakers for their outstanding performance in the field and wishes them success in future endeavors. We would like to thank all the participants for their flamboyant presence and enlivened presentations.

Following on the heels of this successful event, we are excited to announce 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics to be held during June 09-10, 2016 in Dallas, USA and wish that your overwhelming support will make Drug Monitoring-2016 an outstanding event.


Past Reports  Gallery  

Toxicology-2014


The 3rd International Summit on Toxicology & Applied Pharmacology took place inChicago, USA on October 20-22, 2014. The conference was titled: “New Challenges and Innovations in Pharmacological and Toxicological Sciences” and hosted by the OMICS Group. Generous response and active participation was received from the Editorial Board Members of OMICS Group Journals, Toxicology-2014 Organizing Committee Members, as well as from scientists, researchers and leaders in Toxicology.

Students from various parts of the world took active participation in poster presentations. Students who presented well were awarded Best Poster Presentations for their outstanding contribution in the field of Toxicology.

The conference was carried out through various sessions and the discussions were held on the following scientific tracks:

  • Clinical and Forensic Toxicology
  • Mechanistic and Predictive Toxicology
  • Toxicology and Applied Pharmacology
  • Environmental and Occupational Health
  • Application of Stem Cells in Toxicology
  • Risk Assessment of Chemicals in Food
  • Emerging In-vitro Models for the Toxicity Studies
  • Industrial and Metallic Toxicology
  • Developmental and Reproductive Toxicology
  • Computational Toxicology
  • Nanomaterials
  • Venomous Animals and Toxins
  • Countersteps towards Toxicity

The conference was opened by introductions from the honorable guests and members of the keynote forum. On the first day of opening the keynote speakers were,

Gerhard Eisenbrand, University of Kaiserslautern, Germany

Pavel Vodicka, Institute of Experimental Medicine, Czech Republic

Anne Marie Vinggaard, Technical University of Denmark, Denmark

Special session was conducted by Carter Cliff, Cellular Dynamics International, USA on the topic “Pluripotent stem cell models-Application in toxicology and beyond”, Heres-Pulido M E, Universidad Nacional Autónoma de México, Mexico on the topic “The Somatic Mutation and Recombination Test (SMART) in Drosophila melanogaster”.

Symposium conducted by Cinzia Forni from University of Rome Tor Vergata, Italy and Hemant Misra from Prolong Pharmaceuticals, USA and the title of the Symposium is “Stress response in living organisms exposed to pollutants”.

All the speakers gave their fruitful contribution in the form of highly informative presentations and made the conference a great success.

All accepted abstracts have been indexed in OMICS Group Journal of Clinical Toxicologyas a special issue.

We are also obliged to various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Our sincere thanks to Organizing Committee Members for their gracious presence, support and assistance towards Toxicology-2014.


Past Reports  Gallery  

Toxicology-2013


The 2nd International Summit on Toxicology took place in Las Vegas, USA on October 07-09, 2013.The conference was titled: “Insight into the Global Issues of Toxicology” and hosted by the OMICS Group. Generous response and active participation was received from the Editorial Board Members of OMICS Group Journals, Organizing Committee Members, scientists, researchers, clinical experts and leaders from the field of Toxicology.

The conference was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

  • Emerging Concepts in Toxicology
  • Forensic Toxicology
  • Pharmaceutical Toxicology
  • Regulatory Toxicology
  • Analytical Toxicology
  • Medical and Clinical Toxicology
  • In-vitro and In-vivo Toxicology
  • Veterinary Toxicology
  • Microbiology and Toxicology
  • Entomotoxicology
  • Occupational and Environmental Toxicology
  • Metallic Toxicology
  • Countermeasure for Toxins

The conference paved its way by the introductory speeches from Honourable guests and members of the Keynote forum such as;

Bruce A. Fowler, ICF International, USA

John Pierce Wise, University of Southern Maine, USA

Wei Zheng, Purdue University School of Health Sciences, USA

Nikolas P. Lemos, University of California, USA

Rajat Sethi, California Health Sciences University, USA

All the speakers gave their fruitful contribution in the form of highly informative presentations which made the conference a great success. OMICS Group is also obliged to various outside experts, representatives and other eminent personalities who supported the conference by facilitating the discussion forums and sincere appreciations to Organizing Committee Members and Editorial Board members for their gracious presence, support and assistance towards Toxicology-2013.


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 25-26, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
toxicogenomics@omicsgroup.com
Sponsors / Exhibiting / Advertising.
toxicogenomics@conferenceseries.com
General Queries.
toxicogenomics@conferenceseries.net

View Proceedings of Previous Conferences

Toxicogenomics 2015
Toxicogenomics 2014
Toxicogenomics 2013
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.